Investment
Features
FeesSafety
Academy
More
Pluang+

Compare FuelCell Energy Inc (FCEL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

FuelCell Energy IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

FuelCell Energy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? FuelCell Energy Inc trades at $18.74 (market cap $1.62B), while Vertex Pharmaceuticals Incorporated trades at $482.2 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 74.7× FuelCell Energy Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals.

FCELVRTX
Market Cap
$1.62B$121.09B
Sector
IndustrialsHealth
52-Week High
$36.01$529.59
52-Week Low
$3.92$366.54
Enterprise Value
$1.47B$115.83B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

FuelCell Energy Inc

No Aura AI signal available yet.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.

The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About FuelCell Energy Inc

FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.

Read more on FCEL

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX